Study analyzes effect of shift work on prostate cancer

In a recent original article in Deutsches Ärzteblatt International (Dtsch Arztbl Int 112: 463-70), Gael P. Hammer et al. show that shift workers do not develop prostate cancer more frequently than their colleagues who work during the day.

As well as the daily strain of their working lives, shift workers are probably also more likely than other people to develop cancer. While this has been well described for breast cancer, few studies had examined the correlation between shift work and prostate cancer. In a recent original article in Deutsches Ärzteblatt International (Dtsch Arztbl Int 112: 463-70), Gael P. Hammer et al. show that shift workers do not develop prostate cancer more frequently than their colleagues who work during the day.

Shift work is widespread: between approximately one in five and one in six of the working population work shifts. The authors evaluated the personnel and health data of almost 28 000 employees of a chemical company in Rhineland-Palatinate between 1995 and 2005. Some 340 developed prostate cancer, but these included comparable numbers of shift and day workers. This article therefore contradicts the findings of smaller studies, with fewer participants, on the same subject. However, the authors emphasize that their study was the first to analyze the effect of shift work on prostate cancer including such a large number of participants with well documented data.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Mursla Bio announces promising results for EvoLiver test in liver cancer detection